Hepatocellular Carcinoma in NAFLD

Fatty Liver Disease: NASH and Related Disorders

Volumn , Issue , 2007, Pages 263-275

  Ratziu, Vlad ^a   Poynard, Thierry ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cirrhosis; Diabetes; Hepatocellular carcinoma; Nonalcoholic fatty liver disease (NAFLD); Obesity

Indexed keywords

EID: 85031826745     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987438.ch22     Document Type: Chapter

References (84)

1. Teli MR, James OFW, Burt D et al. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9.
2. Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23.
3. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohep- atitis. Hepatology 1999; 30: 1356-62.
4. Powell EE, Cooksley WGE, Hanson R et al. The natural history of non-alcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
5. Lee RG. Non-alcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-8.
6. Bacon BR, Farahvash MJ, Janney CG et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
7. Caldwell SH, Oelsner DH, Iezzoni JC et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
8. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689-92.
9. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-9.
10. Matteoni CA, Younossi ZM, Grämlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
11. Ratziu V, Bonyhay L, Di Martino V et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
12. El-Serag H, Mason A. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
13. Shimada M, Hashimoto E, Taniai M et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-60.
14. Cotrim HP, Parana R, Braga E et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol. 2000; 95: 3018-9.
15. Zen Y, Katayanagi K, Tsuneyama K et al. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001; 51: 127-31.
16. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
17. Marrero JA, Fontana RJ, Su GL et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54.
18. Adami HO, Chow WH, Nyren O et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-7.
19. Lawson DH, Gray JM, McKillop C et al. Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 1986; 61: 945-55.
20. Wideroff L, Gridley G, Mellemkjaer L et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-5.
21. Lu SN, Lin TM, Chen CJ et al. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 1988; 62: 2051-5.
22. Yu MC, Tong MJ, Govindarajan S et al. Non-viral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 1991; 83: 1820-6.
23. La Vecchia C, Negri E, Decarli A et al. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997; 73: 204-7.
24. Hassan MM, Hwang LY, Hatten CJ et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.
25. Lagiou P, Kuper H, Stuver SO et al. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096-9.
26. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462-7.
27. Nair S, Mason A, Eason J et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-5.
28. Adami HO, McLaughlin JK, Hsing AW et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control 1992; 3: 419-25.
29. Di Bisceglie AM, Carithers RL Jr, Gores GJ. Hepatocellular carcinoma. Hepatology 1998; 28: 1161-5.
30. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001; 358: 1405-9.
31. Nelson R, Persky V, Davis F et al. Re: excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1997; 89: 327-8.
32. Braga C, La Vecchia C, Negri E et al. Attributable risks for hepatocellular carcinoma in northern Italy. Eur J Cancer 1997; 33: 629-34.
33. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
34. Wolk A, Gridley G, Svensson M et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21.
35. Moller H, Mellemgaard A, Lindvig K et al. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344-50.
36. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-38.
37. Moore MA, Park CB, Tsuda H. Implications of the hyper- insulinaemia-diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998; 7: 89-107.
38. Istvan J, Murray R, Voelker H. The relationship between patterns of alcohol consumption and body weight. Lung Health Study Research Group. Int J Epidemiol 1995; 24: 543-6.
39. Bruning PF, Bonfrer JM, van Noord PA et al. Insulin resistance and breast-cancer risk. Int J Cancer 1992; 52: 511-6.
40. Kazer RR. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. IntJ Cancer 1995; 62: 403-6.
41. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link?. Cancer Causes Control 1996; 7: 605-25.
42. Singh P, Rubin N. Insulin-like growth factors and binding proteins in colon cancer. Gastroenterology 1993; 105: 1218-37.
43. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276: 60-6.
44. Leffert HL, Koch KS, Moran T et al. Hormonal control of rat liver regeneration. Gastroenterology 1979; 76: 1470-82.
45. McGowan JA, Strain AJ, Bucher NL. DNA synthesis in primary cultures of adult rat hepatocytes in a defined medium: effects of epidermal growth factor, insulin, glucagon, and cyclic-AMP. J Cell Physiol 1981; 108: 353-63.
46. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-20.
47. Bertrand F, Atfi A, Cadoret A et al. A role for nuclear factor kB in the antiapoptotic function of insulin. J Biol Chem 1998; 273: 2931-8.
48. Bertrand F, Desbois-Mouthon C, Cadoret A et al. Insulin antiapoptotic signalling involves insulin activation of the nuclear factor KB-dependent survival genes encoding tumor necrosis factor receptor-associated factor 2 and manganese-superoxide dismutase. J Biol Chem 1999; 274: 30596-602.
49. Lagopoulos L, Sunahara GI, Wurzner H et al. The effects of alternating dietary restriction and ad libitum feeding of mice on the development of diethylnitrosamine- induced liver tumours and its correlation to insulinaemia. Carcinogenesis 1991; 12: 311-5.
50. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 1997; 150: 1071-87.
51. Nishiyama M, Wands JR. Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1992; 183: 280-5.
52. Ito T, Sasaki Y, Wands JR. Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. Mol Cell Biol 1996; 16: 943-51.
53. Tanaka S, Wands JR. A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. J Clin Invest 1996; 98: 2100-8.
54. Bach LA, Rechler MM. Insulin-like growth factors and diabetes. Diabetes Metab Res Rev 1992; 8: 229-57.
55. Davies MJ, Rayman G, Gray IP et al. Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabet Med 1993; 10: 313-20.
56. Daughaday WH. The possible autocrine-paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology 1990; 127: 1-4.
57. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001; 54: 138-44.
58. Koch KS, Shapiro P, Skelly H et al. Rat hepatocyte proliferation is stimulated by insulin-like peptides in defined medium. Biochem Biophys Res Commun 1982; 109: 1054-60.
59. Dunn SE, Kari FW, French J et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667-72.
60. Sell C, Baserga R, Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55: 303-6.
61. Rogler CE, Yang D, Rossetti L et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779-84.
62. Lin SB, Hsieh SH, Hsu HL et al. Antisense oligodeoxynu- cleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem (Tokyo) 1997; 122: 717-22.
63. Rubin R, Baserga R. Insulin-like growth factor-I receptor: its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995; 73: 311-31.
64. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 249-52.
65. Miura M, Surmacz E, Burgaud JL et al. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem 1995; 270: 22639-44.
66. Resnicoff M, Burgaud JL, Rotman HL et al. Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. Cancer Res 1995; 55: 3739-41.
67. Yang S, Lin HZ, Hwang J et al. Hepatic hyperplasia in non-cirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?. Cancer Res 2001; 61: 5016-23.
68. Heston W, Vlhakis G. Genetic obesity and neoplasia. J Natl Cancer Inst 1962; 29: 197-209.
69. Yang S, Zhu H, Li Y et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378: 259-68.
70. Weltman MD, Farrell GC, Liddle C. Increased hepato- cyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-53.
71. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
72. Weltman MD, Farrell GC, Hall P et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33.
73. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
74. Martinez-Chantar ML, Corrales FJ, Martinez-Cruz LA et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 2002; 16: 1292-4.
75. Lu SC, Alvarez L, Huang ZZ et al. Methionine adeno- syltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci USA 2001; 98: 5560-5.
76. Cai J, Mao Z, Hwang JJ et al. Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res 1998; 58: 1444-50.
77. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU et al. Methionine adenosyltransferase II p subunit gene expression provides a proliferative advantage in human hepatoma. Gastroenterology 2003; 124: 940-8.
78. Ockner RK, Kaikaus RM, Bass NM. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology 1993; 18: 669-76.
79. Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the non-genotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor a. J Natl Cancer Inst 1998; 90: 1702-9.
80. Peters JM, Cattley RC, Gonzalez FJ. Role of PPARa in the mechanism of action of the non-genotoxic carcinogen and peroxisome proliferator Wy-14,463. Carcinogenesis 1997; 18: 2029-33.
81. Hashimoto T, Fujita T, Usuda N et al. Peroxisomal and mitochondrial fatty acid p-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor a and peroxisomal fatty acyl-CoA oxidase: genotype correlation with fatty liver phenotype. J Biol Chem 1999; 274: 19228-36.
82. Bass NM. Three for the price of one knockout: a mouse model of a congenital peroxisomal disorder, steatohep- atitis and hepatocarcinogenesis. Hepatology 1999; 29: 606-8.
83. Fan CY, Pan J, Usuda N et al. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisome proliferator-activated receptor a natural ligand metabolism. J Biol Chem 1998; 273: 15639-45.
84. Holden PR, Tugwood JD. Peroxisome proliferator- activated receptor a: role in rodent liver cancer and species differences. J Mol Endocrinol 1999; 22: 1-8.